FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 360:1811-1813 April 30, 2009 Number 18 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

On March 18, 2009, the Cardiovascular and Renal Drugs Advisory Committee of the Food and Drug Administration (FDA) convened to determine whether the antiarrhythmic drug dronedarone should be approved for the reduction of cardiovascular morbidity and mortality among patients with atrial fibrillation or atrial flutter. It has been 10 years since the FDA approved dofetilide, the last antiarrhythmic drug for suppression of atrial fibrillation to reach the U.S. market. Because of an increased risk of torsades de pointes, particularly at the initiation of therapy, dofetilide's label includes a requirement that therapy be initiated in the hospital and monitored by a . . . [Full Text of this Article]

Source Information

Dr. Zimetbaum is the director of clinical cardiology at Beth Israel Deaconess Medical Center and an associate professor of medicine at Harvard Medical School — both in Boston.

This article has been cited by other articles:

• Wyse, D. G. (2009). Cardioversion of Atrial Fibrillation for Maintenance of Sinus Rhythm: A Road to Nowhere. Circulation 120: 1444-1452 [Full Text]